Precision medicine is no longer limited to targeted drug therapy; it has also been adopted in radiation therapy. In the past, radiation beams only matched the height and width of the tumor causing significant damage to the surround tissue. Advances in imaging technology have made it possible to locate and treat the tumor more precisely,…
Dr. Anup Kasi provides in-depth information and answers questions about qualifying for pancreatic cancer clinical trials.
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine combined with chemotherapy after surgery to remove pancreatic cancer.
Researchers are combining TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, to see if they work on pancreatic and other gastrointestinal cancers.
In an immunotherapy clinical trial, Dr. Mark O’Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.